Storage, research and provision to medical institutions of cord blood-derived stem cells

「As of the end of March 2026, the cumulative number of stored samples exceeded 110,000. Because storage-fee revenue continues to accrue from these samples throughout the contract period, growth in the number of stored samples will expand future recurring revenue and contribute to building the company’s stable earnings base.」

「Since the launch of the new storage plan “HOPECELL” in November 2024, market penetration has proceeded smoothly, driving strong growth in the total number of stored cord and cord-blood samples. As of the end of March 2026, the cumulative number of stored samples since the company’s foundation had exceeded 110,000.」

「The new “HOPECELL” storage plan, introduced in November 2024, collects and stores both cord blood and umbilical cord tissue, enabling more reliable storage of valuable cells available only at childbirth. The plan is steadily gaining market traction. As a result, average revenue per customer increased compared with the previous plan, while the number of new umbilical cord storage contracts rose sharply to approximately 2.1 times the year-earlier level.」

「In the regenerative medicine-related business, StemCell Institute (TSE Growth, securities code: 7096; our equity interest: 72.1%) focused on offline marketing, including talks and public relations activities at medical institutions, its main marketing channel, digital marketing, including online advertising and social media, and educational activities such as study sessions for the media, with the aim of reaching its medium-term management target of 20,000 samples stored, equivalent to a storage rate of approximately 3% of domestic births. As a result, all indicators, including the number of stored samples, comprising cord blood and umbilical cords, revenue and profit at every stage, reached new record highs.」

「In the regenerative medicine-related business, revenue reached a new record high as the number of samples stored under StemCell Institute’s cell banking services increased, both for its cord blood storage service, with a market share of approximately 99%, and its umbilical cord storage service, with a 100% share.」

「In the regenerative medicine-related business, StemCell Institute (TSE Growth, securities code: 7096; our equity interest: 72.1%) set new records for both revenue and profit for the cumulative nine-month period. Offline marketing, including talks and public relations activities at medical institutions, mainly obstetric facilities, which had been restricted during the COVID-19 pandemic, recovered substantially and generated synergies with digital marketing, including online advertising and social media. As a result, the company recorded a record-high number of stored samples and is progressing steadily toward its medium-term target of a 3% storage rate relative to the number of births, corresponding to projected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion when achieved.」

「In the regenerative medicine-related business, StemCell Institute (TSE Growth, securities code: 7096; our equity interest: 72.1%) recorded a record-high number of stored samples. Offline marketing, including talks and public relations activities at medical institutions, mainly obstetric facilities, which had been restricted during the COVID-19 pandemic, recovered substantially and generated synergies with digital marketing, including online advertising and social media. The company is progressing steadily toward its medium-term target of a 3% storage rate relative to the number of births, corresponding to projected revenue of approximately ¥6 billion and operating profit of approximately ¥1.8 billion when achieved.」

「For Japan’s first umbilical cord storage service, launched in April 2021, demand for storage has increased since June following the launch of Japan’s first “family cultured conditioned-medium production service,” which cultures umbilical cords and produces and supplies conditioned medium for customers who store samples. The storage rate has consequently exceeded the plan. Although the service’s full contribution to performance will begin from the second quarter onward, monthly revenue reached record highs in each of April, May and June, and revenue for the cumulative first-quarter period also set a new record.」

「The company is also making steady progress in strengthening the operations of the Yokohama Cell Processing Center, which obtained a manufacturing license for specified cell-processing products from the Ministry of Health, Labour and Welfare’s Kanto-Shinetsu Regional Bureau of Health and Welfare on 12 March 2021 and began operating. It has already secured annual processing capacity for approximately 20,000 samples, about three times the previous capacity, which is its medium-term target.」

「In the regenerative medicine-related business, StemCell Institute’s stepped-up digital marketing activities, conducted since the year before last, and Japan’s first umbilical cord storage service, launched in April last year, steadily contributed to improved performance. The company recorded record-high revenue for both the quarter and the cumulative first-half period.」

「Stepped-up digital marketing activities conducted since the year before last and Japan’s first umbilical cord storage service, launched in April last year, contributed to record-high monthly revenue in June and record-high revenue for the cumulative first-quarter period. To prepare for further growth in the number of samples, the company is also strengthening operations at the Yokohama Cell Processing Center and the Second Storage Center, which began operating last year and can handle three times the capacity of the previous facilities.」

「The company is Japan’s largest private cord blood bank, holding 64,063 of the 64,851 cord blood units stored in Japan, representing a 98.8% share (according to the Ministry of Health, Labour and Welfare Health Service Bureau’s Report on Cord Blood Transfers and Related Matters, as of 31 March 2021). In addition to its conventional cord blood service, it will increase awareness of and expand the number of stored samples for its umbilical cord storage service, launched in April last year, through “X (cross) marketing,” which combines digital marketing, including web advertising, SEO and online seminars, with conventional offline marketing, including talks at maternity facilities and childbirth classes, in response to the with- and post-COVID era.」

「In the regenerative medicine-related business, StemCell Institute recorded record-high monthly revenue in December and record-high revenue for the cumulative nine-month period, supported by stepped-up digital marketing activities conducted since the previous fiscal year and Japan’s first umbilical cord storage service, launched in April this year.」

「The company also announced its results for the first quarter of the fiscal year ended March 2022 on 5 August, the same date as we did. For details, please refer to the company’s earnings report.」

「In April this year, we launched a new umbilical cord storage service based on the results of joint research with the University of Tokyo Institute of Medical Science Hospital. We will also work with medical and research institutions to collect and store cells derived from other birth-related tissues, known as perinatal tissue-derived cells.」

「In the regenerative medicine business, StemCell Institute continues to be affected by the COVID-19 pandemic in terms of sales, but the digital marketing on which it has focused as a new marketing channel is steadily producing results. As of January, the number of requests for information, a leading KPI, was running well above its previous record high.」

「In September, we began joint research with the Institute of Medical Science, the University of Tokyo and the University of Tokyo Hospital on congenital structural abnormalities, including cleft palate, esophageal atresia and abdominal wall defects, with the aim of realizing Japan’s first clinical application of cells derived from autologous umbilical cords.」

「In regenerative medicine, StemCell Institute, a private umbilical cord blood bank with approximately 99% of the domestic market, is working to strengthen and expand its business foundation over the medium to long term. Although the COVID-19 pandemic affected access to medical facilities, the web marketing initiatives pursued as a new approach have begun contributing to revenue. The company is also conducting joint research with the University of Tokyo Institute of Medical Science Hospital on an autologous umbilical cord storage service and is making the necessary preparations, including construction of a new CPC (cell processing center), to launch the business next year.」

「To prepare for the expansion of the business, a new CPC (cell processing center) is currently being built in Yokohama with processing capacity 1.5 times that of the current facility, and it is scheduled to begin operations in January next year.」

「StemCell Institute, Japan’s largest private umbilical cord blood bank, continued to grow steadily, with revenue up 51.1% year on year. As of the end of last December, the number of customers in storage exceeded 52,000 and its domestic share was approximately 99%.」

「The cumulative number of customers in storage has surpassed 50,000, and the number of contracted samples per month continues to grow. Clinical trials aimed at commercializing autologous umbilical cord blood treatment are progressing at Kochi University School of Medicine, Osaka City University School of Medicine and other institutions, while awareness and demand for umbilical cord blood storage are increasing in Japan.」

「At StemCell Institute, Japan’s largest private umbilical cord blood bank, the number of samples in storage in the first quarter increased 66.0% year on year. In a clinical trial aimed at commercializing autologous umbilical cord blood treatment, the Phase I trial at Kochi University School of Medicine for brain disorders including pediatric cerebral palsy was completed successfully, with favorable results reported.」

「At StemCell Institute, which operates Japan’s largest umbilical cord blood bank in the advanced healthcare sector, with approximately 99% of the share of new storage customers, new storage volumes continued to perform strongly. Revenue increased 31.3% year on year and operating profit increased 93.4%. Clinical research on umbilical cord blood has begun to expand actively in Japan, and its results are eagerly anticipated, with demand for storage expected to grow further. To prepare for this, we are actively strengthening our workforce and business infrastructure.」

「At StemCell Institute, the number of new contracts reached monthly record highs twice in the first half, firmly raising the base from previous levels, and we believe the business has entered a full-scale growth trajectory. With a view to expanding the cell banking business and entering the cell pharmaceutical business in the future, we are also advancing basic and clinical research jointly with various universities.」

「StemCell Institute, which operates Japan’s largest private umbilical cord blood bank in the advanced healthcare sector, with approximately 99% of domestic storage volume (based on new annual storage; survey by the Health Service Bureau of the Ministry of Health, Labour and Welfare), continued to grow steadily and achieved record-high revenue in June. The number of customers in storage was 44,028 as of the end of June.」

「StemCell Institute, which operates a private umbilical cord blood bank in the advanced healthcare sector, achieved record-high revenue. As of the end of March, the number of customers in storage was 43,207, and its domestic share of storage volume was approximately 99% (based on new annual storage; survey by the Health Service Bureau of the Ministry of Health, Labour and Welfare).」

「StemCell Institute, the leading provider of umbilical cord blood-derived stem cell storage, a field attracting growing attention in regenerative medicine, continued to steadily increase its customer base, reaching 41,889 customers in storage as of the end of September this year. Clinical research under way at Kochi University School of Medicine, the first in Japan for brain disorders including pediatric cerebral palsy, is progressing smoothly.」

「StemCell Institute, which operates a long-term storage business for umbilical cord blood-derived stem cells for regenerative and cell therapies and the treatment of intractable hematological diseases and holds approximately 95% of the domestic market, had 41,128 customers in storage as of the end of June this year, continuing its steady growth. Kochi University School of Medicine is currently conducting clinical research under the Act on Securing Safety of Regenerative Medicine into autologous umbilical cord blood mononuclear cell transfusions for brain disorders including pediatric cerebral palsy, and the results are eagerly anticipated.」

「StemCell Institute, which holds approximately 95% of the domestic market, saw the number of new customers placing samples in storage rise approximately 7% year on year, bringing the number of customers in storage to 40,382 as of the end of March this year. Since January, Kochi University School of Medicine has been conducting clinical research under the Act on Securing Safety of Regenerative Medicine into autologous umbilical cord blood mononuclear cell transfusions for brain disorders including pediatric cerebral palsy.」

「Last December, Kochi University filed with the Ministry of Health, Labour and Welfare a notification of a clinical trial using umbilical cord blood to treat children with cerebral palsy under the Act on Securing Safety of Regenerative Medicine. Preparations are currently under way for the trial, which is expected to use cells stored by the company.」

「StemCell Institute, which provides long-term storage of umbilical cord blood-derived stem cells for regenerative and cell therapies and the treatment of intractable hematological diseases, currently holds approximately 90% of the domestic market.」

「StemCell Institute is engaged in the separation and storage of umbilical cord blood and research and development related to stem cells for transplant treatments for intractable hematological diseases, such as leukemia and aplastic anemia between siblings, as well as for regenerative and cell therapies expected in the near future.」